Non-antiarrhythmic agents for prevention of postoperative atrial fibrillation: Role of statins

Current Opinion in Anaesthesiology

Volumn 20, Issue 1, 2007, Pages 53-56

  Blanchard, Lawrence ^a   Collard, Charles D ^a  

^a ST LUKE S EPISCOPAL HOSPITAL   (United States)

Author keywords

Arrhythmia; Hydroxymethylglutaryl coenzyme A reductase inhibitors; Inflammation; Prevention; Surgery

Indexed keywords

ANTIARRHYTHMIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; DIGOXIN; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SERUM AMYLOID A; TUMOR NECROSIS FACTOR ALPHA;

ACUTE CORONARY SYNDROME; ADJUVANT THERAPY; CARDIOPULMONARY BYPASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFIDENCE INTERVAL; CORONARY ARTERY BYPASS GRAFT; DISEASE MARKER; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; EXTRACELLULAR MATRIX; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART PROTECTION; HEART SURGERY; HUMAN; INFLAMMATION; INVASIVE PROCEDURE; KAPLAN MEIER METHOD; KIDNEY DYSFUNCTION; LONG TERM CARE; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PERIOPERATIVE PERIOD; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROPHYLAXIS; RELIABILITY; REVIEW; RISK FACTOR; RISK REDUCTION; STROKE;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; POSTOPERATIVE COMPLICATIONS; RISK FACTORS;

EID: 33846065206     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/ACO.0b013e328013d9fd     Document Type: Review

References (53)

1. Viskin S, Barron HV, Heller K, et al. The treatment of atrial fibrillation: pharmacologic and nonpharmacologic strategies. Curr Probl Cardiol 1997; 22:37-108.
2. Mitchell LB, Crystal E, Heilbron B, Page P. Atrial fibrillation following cardiac surgery. Can J Cardiol 2005; 21 (Suppl B):45B-50B.
3. Hogue CW Jr, Hyder ML. Atrial fibrillation after cardiac operation: risks, mechanisms, and treatment. Ann Thorac Surg 2000; 69:300-306.
4. Prystowsky EN. Management of atrial fibrillation: therapeutic options and clinical decisions. Am J Cardiol 2000; 85 (10A):3D-11D.
5. McKeown PP, Gutterman D. Executive summary: American College of Chest Physicians guidelines for the prevention and management of postoperative atrial fibrillation after cardiac surgery. Chest 2005; 128 (2 Suppl):1S-5S. The current American College of Chest Physicians guidelines for the prevention and management of postoperative atrial fibrillation after cardiac surgery.
6. Bharucha DB, Kowey PR. Management and prevention of atrial fibrillation after cardiovascular surgery. Am J Cardiol 2000; 85 (10A):20D-24D.
7. Mascitelli L, Pezzetta F. Obesity, inflammation, and risk of atrial fibrillation or flutter. Am J Med 2006; 119:e9.
8. Pan M, Zhu JH, Jiang WP, et al. Inflammation: A possible pathogenic link to atrial fibrillation. Med Hypotheses 2006; 67:1305-1307. Review of literature linking the pathogenesis of AF to inflammation.
9. Shiroshita-Takeshita A, Schram G, Lavoie J, Nattel S. Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. Circulation 2004; 110:2313-2319.
10. Aviles RJ, Martin DO, Apperson-Hansen C, et al. Inflammation as a risk factor for atrial fibrillation. Circulation 2003; 108:3006-3010.
11. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995; 92:1954-1968.
12. Engelmann MD, Svendsen JH. Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J 2005; 26:2083-2092. Review of literature linking the pathogenesis of AF to inflammation.
13. Liu T, Li GP, Huang TG. Anti-inflammatory therapies in atrial fibrillation. Int J Cardiol 2005; 104:359-360.
14. Horne BD, Muhlestein JB, Carlquist JF, et al. Statin therapy interacts with cytomegalovirus seropositivity and high C-reactive protein in reducing mortality among patients with angiographically significant coronary disease. Circulation 2003; 107:258-263.
15. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361:2005-2016.
16. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333:1301-1307.
17. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279:1615-1622.
18. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339:1349-1357.
19. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335:1001-1009.
20. Chan AW, Bhatt DL, Chew DP, et al. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation 2002; 105:691-696.
21. Chan AW, Bhatt DL, Chew DP, et al. Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation 2003; 107:1750-1756.
22. Herrmann J, Lerman A, Baumgart D, et al. Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction. Circulation 2002; 106:2180-2183.
23. Ford ES, Giles WH. Serum C-reactive protein and self-reported stroke: findings from the Third National Health and Nutrition Examination Survey. Arterioscler Thromb Vasc Biol 2000; 20:1052-1056.
24. Young-Xu Y, Jabbour S, Goldberg R, et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 2003; 92:1379-1383.
25. Poldermans D, Bax JJ, Kertai MD, et al. Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery. Circulation 2003; 107:1848-1851.
26. Dotani MI, Elnicki DM, Jain AC, Gibson CM. Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting. Am J Cardiol 2000; 86:1128-1130.
27. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997; 336:153-162.
28. Durazzo AE, Machado FS, Ikeoka DT, et al. Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial. J Vasc Surg 2004; 39:967-975.
29. Abbruzzese TA, Havens J, Belkin M, et al. Statin therapy is associated with improved patency of autogenous infrainguinal bypass grafts. J Vasc Surg 2004; 39:1178-1185.
30. Kertai MD, Boersma E, Westerhout CM, et al. Association between long-term statin use and mortality after successful abdominal aortic aneurysm surgery. Am J Med 2004; 116:96-103.
31. Antonini-Canterin F, Zuppiroli A, Popescu BA, et al. Effect of statins on the progression of bioprosthetic aortic valve degeneration. Am J Cardiol 2003; 92:1479-1482.
32. O'neil-Callahan K, Katsimaglis G, Tepper MR, et al. Statins decrease perioperative cardiac complications in patients undergoing noncardiac vascular surgery. The Statins for Risk Reduction in Surgery (StaRRS) study. J Am Coll Cardiol 2005; 45:336-342. Retrospective study using multivariate analysis to demonstrate statins reduce postoperative cardiac complications in patients undergoing noncardiac surgery.
33. Clark LL, Ikonomidis JS, Crawford FA Jr, et al. Preoperative statin treatment is associated with reduced postoperative mortality and morbidity in patients undergoing cardiac surgery: an 8-year retrospective cohort study. J Thorac Cardiovasc Surg 2006; 131:679-685. Retrospective study of 3829 patients using multivariate analysis to demonstrate statins reduce postoperative cardiac complications in patients undergoing cardiac surgery.
34. Patti G, Chello M, Candura D, et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation 2006; 114:1455-1461. Randomized, controlled trial demonstrating statins reduce postoperative AF after cardiac surgery.
35. Ozaydin M, Dogan A, Varol E, et al. Statin use before by-pass surgery decreases the incidence and shortens the duration of postoperative atrial fibrillation. Cardiology 2006; 107:117-121. Retrospective study of 362 patients using multivariate analysis to demonstrate statins reduce postoperative AF in patients undergoing cardiac surgery.
36. Amar D, Zhang H, Heerdt PM, et al. Statin use is associated with a reduction in atrial fibrillation after noncardiac thoracic surgery independent of C-reactive protein. Chest 2005; 128:3421-3427.
37. Pan W, Pintar T, Anton JLV, et al. Statins are associated with a reduced incidence of perioperative mortality following coronary artery bypass graft surgery. Circulation 2004; 110 (11 suppl 1):45-49.
38. Collard CD, Body SC, Shernan SK, et al. Preoperative statin therapy is associated with reduced cardiac mortality after coronary artery bypass graft surgery. J Thorac Cardiovasc Surg 2006; 132:392-400. Multicenter, multinational study demonstrating not only that statins are associated with reduced postoperative morbidity, but that postoperative discontinuation of statins is associated with worsened outcomes.
39. Chello M, Patti G, Candura D, et al. Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery. Crit Care Med 2006; 34:660-667. Randomized, controlled trial which demonstrates that pretreatment with statins reduces inflammatory cytokine release and neutrophil adhesion molecule expression following CABG surgery.
40. Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001; 286:64-70.
41. Kinlay S, Schwartz GG, Olsson AG, et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 2003; 108:1560-1566.
42. Brown WV. Benefits of statin therapy in patients with special risks: coronary bypass surgery, stable coronary disease, and acute coronary syndromes. Clin Cardiol 2003; 26 (4 Suppl 3):III13-III18.
43. Node K, Fujita M, Kitakaze M, et al. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 2003; 108:839-843.
44. Shishehbor MH, Brennan ML, Aviles RJ, et al. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 2003; 108:426-431.
45. Chen J, Nagasawa Y, Zhu BM, et al. Pravastatin prevents arrhythmias induced by coronary artery ischemia/reperfusion in anesthetized normocholesterolemic rats. J Pharmacol Sci 2003; 93:87-94.
46. Lefer AM, Campbell B, Shin YK, et al. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation 1999; 100:178-184.
47. Naidu BV, Woolley SM, Farivar AS, et al. Simvastatin ameliorates injury in an experimental model of lung ischemia-reperfusion. J Thorac Cardiovasc Surg 2003; 126:482-489.
48. Wan MX, Schramm R, Klintman D, et al. A statin-based inhibitor of lymphocyte function antigen-1 protects against ischemia/reperfusion-induced leukocyte adhesion in the colon. Br J Pharmacol 2003; 140:395-401.
49. Cipollone F, Fazia M, Iezzi A, et al. Suppression of the functionally coupled cyclooxygenase-2/prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans. Circulation 2003; 107:1479-1485.
50. Lazar HL, Bao Y, Zhang Y, Bernard SA. Pretreatment with statins enhances myocardial protection during coronary revascularization. J Thorac Cardiovasc Surg 2003; 125:1037-1042.
51. Marin F, Pascual DA, Roldan V, et al. Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting. Am J Cardiol 2006; 97:55-60. Study demonstrating that statin use may protect against postoperative AF following CABG surgery due to alterations in extracellular matrix remodeling.
52. Abinader EG. Usefulness of statins in protecting against atrial fibrillation. Am J Cardiol 2004; 94:1104.
53. Kumagai K, Nakashima H, Saku K. The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc Res 2004; 62:105-111.